Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Unfractionated heparin (UFH) is a natural agent widely used to prevent clot formation in vessels. Unfractionated heparin is a fast-acting blood thinner, which works with antithrombin, a natural protein in the body, to block clot formation. UFH is administered to patient intravenously into an arm vein or as a subcutaneous injection under the skin. UFH can also be administrated orally. However, oral absorption of unfractionated heparin is poor, owing to their size and anionic structure. UFH is not absorbed properly from the gastrointestinal tract when taken orally.

Unfractionated heparin is majorly used in deep venous thrombosis (DVT), pulmonary embolism (PE), and venous thromboembolism (VTE) in patients with increased postoperative complications. Unfractionated heparin is the preferred treatment for patients at high risk of bleeding complications, owing to its short activity and reversibility and its reversible anticoagulant effect. Additionally, UTH offers various advantages over other types of heparin, owing to its ability to rapidly enter into the blood stream and less reliant to kidney for extraction. UTH is a preferred anticoagulant option for pregnant women, as it does not cross the placenta, and thus is considered as safe for the fetus.

Unfractionated Heparin Market Drivers

Growth of unfractionated heparin market is increasing, owing to the increasing incidence of thromboembolic disorders such as deep vein thrombosis and pulmonary embolism, and among others. According to the data findings published in the Centers for Disease Control and Prevention (CDC), in February 2018, 900,000 people are affected (1 to 2 per 1,000) each year in the U.S. due to the deep venous thromboembolism and Pulmonary Embolism (DVT/PE). According to data published in the Circulation Research Journal: a journal of the American Heart Association, in 2016, the incidence of venous thromboembolism (VTE) increases with increasing age. According to the same source, in the U.S., study estimated the age-stratified incidence showing 143 per 100000 among ages 40 to 49 years, 200 per 100 000 among ages 50 to 59 years, 391 per 100000 among ages 60 to 69 years, 727 per 100000 among ages 70 to 79 years, and 1134 per 100000 among ages ≥80 years. Additionally, the low awareness regarding the pulmonary embolism and deep-vein thrombosis showing the negligence towards the early diagnosis of these condition. Moreover, healthcare regularity organizations are engaged in increasing the awareness for the same, which will expected to drive the unfractionated heparin market in near future.

However, adverse effects of unfractionated heparin during treatment, poses as a major restraint for growth of the unfractionated heparin market. Heparin?induced thrombocytopenia (HIT), an adverse reaction occurring during treatment with heparin, is associated with inconsistent increase in the clotting causing further complications. For instance, according to the data published in American Society of Hematology in 2017, Heparin-induced thrombocytopenia (HIT) is heparin’s most clinically relevant non-hemorrhagic complication. Furthermore, adults receiving heparin formulation for medical or general surgical indications are at higher risk for HIT than pediatric or obstetric patients.

Moreover, cost-effectiveness of low-molecular weight heparin over the unfractionated heparin in venous thromboembolism (VTE) prevention in critical illness, limits the adoption of unfractionated heparin. According to the data published in the Journal of American Medical Association (AMA), in November 2014, hospital costs per patient using low-molecular weight heparin were a median of US$ 39,508 compared with US$ 40,805 on unfractionated heparin. Moreover, low-molecular weight heparin was found to be more effective and least costly in treating VTE.

Unfractionated Heparin Market - Regional Analysis

On the basis of region, the unfractionated heparin market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds a leading position in the global unfractionated heparin market, owing to increasing prevalence of deep venous thromboembolism and Pulmonary Embolism in the region. For instance, according to the Centers for Disease Control and Prevention (CDC), February 2018 data findings, around 60,000 to 100,000 people are estimated to die due to DVT/PE, in the U.S. Moreover, 10% to 30% of people die within one month from diagnosis. Additionally, according to the same source, around 5% to 8% of the U.S. population has one of several genetic risk factors, such as inherited thrombophilias, which increases the risk for thrombosis. 

Unfractionated Heparin Market Competitive Landscape

Some of the key players operating in the unfractionated heparin market are B. Braun Melsungen AG, Pfizer, Inc., Baxter International Inc., Siemens Ag, Sagent Pharmaceuticals, Inc., and LEO Pharma A/S.

Research advancements in unfractionated heparin are expected to create new applications in the treatment of Chronic Obstructive Pulmonary Disease (COPD). A pilot study performed at the University of Portsmouth in December 2017, evaluated that, the use of inhaled nebulized unfractionated heparin is an effective treatment for moderate-to-severe COPD. Unfractionated heparin significantly improves the lung function and reduces labored breathing.

Unfractionated Heparin Market Taxonomy:

By Source

  • Bovine
  • Porcine

By Application:

  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Arterial Embolism
  • Others

By End Users:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Academic and Research Organizations

By Geography:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.

Data Triangulation Methodology | Coherent Market Insights

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Market Analysis | Coherent Market Insights

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.